Executive Director, Medical Education Programs Stanford UniversityExecutive Director, Medical Education ProgramsStanford, CA$206,749–$242,668 / yearReporting to the Assistant Dean for Educational Programs and Services, the Executive Director is responsible for translating academic vision into sustainable operational models that ensure consistency, compliance, and high-quality educational experiences across departments and clinical sites. Within the Stanford School of Medicine, Educational Programs and Services (EPS) plays a central role in advancing the school's educational mission by supporting a broad community of students, trainees, and faculty across the medical education continuum.
Executive Director, GCP QA (Good Clinical Practice, Quality Assurance) Revolution Medicines, Inc.Executive Director, GCP QA (Good Clinical Practice, Quality Assurance)Redwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Minimum of 15 years of experience in the pharmaceutical or biotechnology industry, including at least 10 years in GCP QA or clinical quality leadership roles, with demonstrated experience leading and hosting regulatory inspections (e.g., FDA BIMO, EMA, MHRA, PMDA).
Executive Director Quality Assurance, External Manufacturing VaxcyteExecutive Director Quality Assurance, External ManufacturingSan Carlos, California$300,000–$350,000 / yearReports to: Vice President, Quality Assurance Location: San Carlos, CA Work Arrangement (may be adjusted based on business needs, job responsibilities, or changes to company policy): Hybrid (minimum of 3 days per week onsite) Compensation: The compensation package will be competitive and includes comprehensive benefits and an equity component. The Executive Director, Quality Assurance, External Manufacturing is responsible for leading the External Manufacturing Quality function and executing the quality strategy across Vaxcyte’s global network of Contract Development and Manufacturing Organizations (CDMOs) and external partners.
Executive Director, Global Privacy Revolution Medicines IncExecutive Director, Global PrivacyRedwood City, CAThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Reporting to the Vice President, Compliance, this role serves as a key advisor to the General Counsel (GC) and other senior executives on global privacy, data protection, and responsible data use, while fostering a culture of privacy-by-design across all business functions worldwide.
Executive Director, Gxp Quality And Compliance Revolution Medicines, Inc.Executive Director, Gxp Quality And ComplianceRedwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Preferred Skills: Experience leading global GxP compliance programs across both clinical development and commercial product environments, including inspection readiness, launch readiness, and post-approval compliance oversight.
Executive Director The Salvation Army USAExecutive DirectorSan Francisco, CA$170,000–$175,000 / yearServe as the primary contact to all contract partners and licensing agencies, including San Francisco Department of Public Health, Department of Homelessness and Supportive Housing, California Department of Health Care Services, UCSF Hospital, and Adult Probation. Employees must agree and understand that their services are a necessary part of The Army's religious purposes and their work-related conduct must not conflict with, interfere with, or undermine such religious programs or The Army's religious purposes.
Executive Director, GCP QA (Good Clinical Practice, Quality Assurance) Revolution MedicinesExecutive Director, GCP QA (Good Clinical Practice, Quality Assurance)Redwood City, California$265,000–$331,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Minimum of 15 years of experience in the pharmaceutical or biotechnology industry, including at least 10 years in GCP QA or clinical quality leadership roles, with demonstrated experience leading and hosting regulatory inspections (e.g., FDA BIMO, EMA, MHRA, PMDA).
Executive Director, Innovation Banking Fifth Third BankExecutive Director, Innovation BankingSan Francisco, California$121,900–$262,100 / yearSuccessful candidates will demonstrate a higher degree of proficiency (typically from 8+ years of practical experience or advanced academic exposure) across the following areas: Client Advisory & Relationship Management – Ability to lead conversations, build trust, and deliver tailored solutions that deepen client relationships. . Provides support to the Capital Markets businesses by assessing whether securities products and capital markets services would be appropriate for a particular client and working with the Capital Markets teams to provide those products and services to clients. .
Executive Director, Digital Enablement VaxcyteExecutive Director, Digital EnablementSan Carlos, California$288,000–$335,000 / yearReports to: Chief Commercial Officer Location: US – Philadelphia/Remote Work Arrangement (may be adjusted based on business needs, job responsibilities, or changes to company policy): Remote Compensation: The compensation package will be competitive and includes comprehensive benefits and an equity component. Own and maintain a commercial product roadmap that treats each digital capability — CRM, marketing technology, field enablement, analytics, AI tools — as a discrete product with a use case, a user, a success metric, and a release schedule.
Executive Director, GCP QA Good Clinical Practice, Quality Assurance Revolution Medicines IncExecutive Director, GCP QA Good Clinical Practice, Quality AssuranceRedwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Minimum of 15 years of experience in the pharmaceutical or biotechnology industry, including at least 10 years in GCP QA or clinical quality leadership roles, with demonstrated experience leading and hosting regulatory inspections (e.g., FDA BIMO, EMA, MHRA, PMDA).
Executive Director, Global Patient Safety Quality And Compliance - Pharmacovigilance Revolution Medicines, Inc.Executive Director, Global Patient Safety Quality And Compliance - PharmacovigilanceRedwood City, CA$265,000–$331,000 / yearThe responsibilities of this role include oversight of the PV-QMS, PV training strategy, PV controlled documentation, inspection and audit management, ensuring inspection readiness, Corrective Action Preventive Action (CAPA) management, Quality Assurance (QA), and maintenance of Good Clinical Practice (GCP), and Good Pharmacovigilance Practices (GVP) in partnership with GPS management, QA, and staff. This critical role will require strategic thinking, expert knowledge of global PV regulations (i.e. GCP, GVP), the ability to influence and communicate ideas effectively, results orientation, collaboration with cross-functional teams, technical expertise, and vendor management skills to ensure compliance with regulatory requirements to safeguard patient well-being.
Executive Director, Early Clinical Development Revolution Medicines, Inc.Executive Director, Early Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Clinical Supply Chain Revolution Medicines, Inc.Executive Director, Clinical Supply ChainRedwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Executive Director, Computational Systems Biology Revolution Medicines, Inc.Executive Director, Computational Systems BiologyRedwood City, CA$265,000–$331,000 / yearThe individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Clinical Development Revolution Medicines, Inc.Executive Director, Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
NewTax Equity Originator - Executive Director Wells Fargo BankTax Equity Originator - Executive DirectorSan Francisco, California$215,000–$355,000 / yearLead cross-functional initiatives to develop new products or asset classes, enter new markets, or build new systems which create incremental revenue, increase profitability, demonstrate market leadership, capture internal efficiencies, and provide avenues for growth. They are accountable for execution of all applicable risk programs (Credit, Market, Financial Crimes, Operational, Regulatory Compliance), which includes effectively following and adhering to applicable Wells Fargo policies and procedures, appropriately fulfilling risk and compliance obligations, timely and effective escalation and remediation of issues, and making sound risk decisions.
NewDEPUTY EXECUTIVE DIRECTOR People With Disabilities FoundationDEPUTY EXECUTIVE DIRECTORSan Francisco, CA$78,000–$82,000 / year3. Knowledge of GAAP and bookkeeping, IT skills, employment laws and HR skills, working with and resolving vendor disputes, and nonprofit tax return filing (we have a CPA). 2. General knowledge of disability civil rights and Social Security/SSI disability necessary to administratively oversee PWDF’s programs or equivalent experience.
Executive Director, GxP Quality and Compliance Revolution MedicinesExecutive Director, GxP Quality and ComplianceRedwood City, California$265,000–$331,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. 15+ years of progressive experience in GxP Quality and Compliance within the pharmaceutical, biotechnology, medical device, or related life sciences industry with extensive knowledge of FDA regulations, ICH Guidelines, EU GMP, and global GxP requirements.
Executive Director, IT Vendor Management Hewlett Packard EnterpriseExecutive Director, IT Vendor ManagementSan Jose, CA$196,000–$429,000 / yearJob Description: Primary Responsibilities: Software Spend Audit and Cost Takeout: Own a comprehensive audit of HPE's global IT software portfolio across all SaaS subscriptions, on-premises licenses, maintenance agreements, and acquired-entity software obligations, establishing a total cost of ownership baseline within 90 days. Telecommunications Cost Rationalization: Own commercial oversight of all HPE enterprise telecommunications obligations including network services, voice and data contracts, carrier agreements, colocation, and connectivity at the enterprise and site level.
Executive Director, IT Vendor Management Hewlett Packard Enterprise CoExecutive Director, IT Vendor ManagementSan Jose, CA$196,000–$429,000 / yearJob Description: Primary Responsibilities: Software Spend Audit and Cost Takeout: Own a comprehensive audit of HPE's global IT software portfolio across all SaaS subscriptions, on-premises licenses, maintenance agreements, and acquired-entity software obligations, establishing a total cost of ownership baseline within 90 days. Telecommunications Cost Rationalization: Own commercial oversight of all HPE enterprise telecommunications obligations including network services, voice and data contracts, carrier agreements, colocation, and connectivity at the enterprise and site level.